- Home
- GRDN vs WGS Comparison
GRDN vs WGS Comparison
Compare GRDN & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRDN
- WGS
- Stock Information
- Founded
- GRDN 2004
- WGS 2017
- Country
- GRDN United States
- WGS United States
- Employees
- GRDN N/A
- WGS N/A
- Industry
- GRDN Retail-Drug Stores and Proprietary Stores
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- GRDN Consumer Staples
- WGS Technology
- Exchange
- GRDN Nasdaq
- WGS Nasdaq
- Market Cap
- GRDN 1.1B
- WGS 1.1B
- IPO Year
- GRDN 2024
- WGS N/A
- Fundamental
- Price
- GRDN $17.14
- WGS $56.00
- Analyst Decision
- GRDN
- WGS Strong Buy
- Analyst Count
- GRDN 0
- WGS 5
- Target Price
- GRDN N/A
- WGS $45.80
- AVG Volume (30 Days)
- GRDN 348.2K
- WGS 603.9K
- Earning Date
- GRDN 11-15-2024
- WGS 10-29-2024
- Dividend Yield
- GRDN N/A
- WGS N/A
- EPS Growth
- GRDN N/A
- WGS N/A
- EPS
- GRDN N/A
- WGS N/A
- Revenue
- GRDN $1,119,255,000.00
- WGS $243,657,000.00
- Revenue This Year
- GRDN N/A
- WGS $31.32
- Revenue Next Year
- GRDN N/A
- WGS $14.29
- P/E Ratio
- GRDN $80.32
- WGS N/A
- Revenue Growth
- GRDN 14.66
- WGS 3.06
- 52 Week Low
- GRDN $14.16
- WGS $1.16
- 52 Week High
- GRDN $20.10
- WGS $61.89
- Technical
- Relative Strength Index (RSI)
- GRDN N/A
- WGS 68.08
- Support Level
- GRDN N/A
- WGS $51.04
- Resistance Level
- GRDN N/A
- WGS $61.41
- Average True Range (ATR)
- GRDN 0.00
- WGS 3.77
- MACD
- GRDN 0.00
- WGS 0.70
- Stochastic Oscillator
- GRDN 0.00
- WGS 72.59
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.